NCT07154524 Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
| NCT ID | NCT07154524 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | Chronic Inflammatory Demyelinating Polyneuropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-08-27 |
| Primary Completion | 2029-02-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2025-08-27 with a primary completion date of 2029-02-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to intravenous immunoglobulins (IVIg) and methyl-prednisolone (MP). For this purpose, approximately 140 patients with CIDP will be included within the framework of the German multicenter network "Kompetenznetz Peripherer Nerv" (KKPNS). The study will be purely observational. IA will be performed as an escalation therapy, i.e., in patients who did not respond to IVIg and/or MP treatment. Patients will be included in the study during ongoing IVIg or MP treatment and switched to IA during the 18-month observation period in case of an insufficient response. IA will be performed according to the therapeutic scheme of each participating center. A non-mandatory recommendation for number of sessions, treatment volumes, and frequency will be given (see below). Six-month follow-up visits including collection of standardized clini-cal data will be performed.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of CIDP based on the EAN/PNS Guidelines on Diagnosis and Treatment of CIDP13 * age ≥ 18 years * Willing and capable of giving written informed consent * Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline Exclusion Criteria: * none
Contact & Investigator
Johannes Dorst
PRINCIPAL INVESTIGATOR
University of Ulm
Frequently Asked Questions
Who can join the NCT07154524 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Inflammatory Demyelinating Polyneuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07154524 currently recruiting?
Yes, NCT07154524 is actively recruiting participants. Contact the research team at johannes.dorst@uni-ulm.de for enrollment information.
Where is the NCT07154524 trial being conducted?
This trial is being conducted at Ulm, Germany.
Who is sponsoring the NCT07154524 clinical trial?
NCT07154524 is sponsored by University of Ulm. The principal investigator is Johannes Dorst at University of Ulm. The trial plans to enroll 140 participants.